Piperacillin-tazobactam: Difference between revisions
From IDWiki
No edit summary |
m (Text replacement - " species]]" to "]]") |
||
| Line 33: | Line 33: | ||
|≤14 |
|≤14 |
||
|- |
|- |
||
| − | |[[Acinetobacter |
+ | |[[Acinetobacter]] |
| |
| |
||
|≤16/4 |
|≤16/4 |
||
Revision as of 22:53, 7 February 2022
Background
Clinical Breakpoints
| Species | ECV (μg/mL) | Breakpoints (μg/mL) | Breakpoints (mm) | ||||
|---|---|---|---|---|---|---|---|
| S | I | R | S | I | R | ||
| Enterobacterales | ≤16/4 | 32/4-64/4 | ≥128/4 | ≥21 | 18-20 | ≤17 | |
| Pseudomonas aeruginosa | ≤16/4 | 32/4-64/4 | ≥128/4 | ≥21 | 15-20 | ≤14 | |
| Acinetobacter | ≤16/4 | 32/4-64/4 | ≥128/4 | ≥21 | 18-20 | ≤17 | |
| Other non-Enterobacterales | ≤16/4 | 32/4-64/4 | ≥128/4 | ||||
| Anaerobes | ≤16/4 | 32/4-64/4 | ≥128/4 | ||||
| Haemophilus influenzae and Haemophilus parainfluenzae | ≤1/4 | — | ≥2/4 | ≥21 | — | — | |
| Gram-positive bacteria | susceptibility predicted by penicillin | ||||||
